Role of ICOS in Systemic Lupus Erythematosus
Author Information
Author(s): Kawamoto Manabu, Harigai Masayoshi, Hara Masako, Kawaguchi Yasushi, Tezuka Katsunari, Tanaka Michi, Sugiura Tomoko, Katsumata Yasuhiro, Fukasawa Chikako, Ichida Hisae, Higami Satomi, Kamatani Naoyuki
Primary Institution: Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Hypothesis
ICOS is involved in the immunopathogenesis of systemic lupus erythematosus (SLE) and may serve as a therapeutic target.
Conclusion
The study suggests that ICOS co-stimulation enhances T cell activation and antibody production in SLE, indicating its potential as a therapeutic target.
Supporting Evidence
- ICOS was over-expressed in peripheral blood CD4+ T cells from patients with active SLE.
- ICOS co-stimulation significantly increased the production of IFN-γ, IL-4, and IL-10 in both SLE and normal T cells.
- SLE T cells with ICOS co-stimulation enhanced the production of IgG anti-double-stranded DNA antibodies by autologous B cells.
Takeaway
This study found that a protein called ICOS helps T cells in people with lupus to be more active, which might lead to more antibodies that can cause problems.
Methodology
The study involved analyzing peripheral blood T cells from patients with active and inactive SLE and normal controls, using flow cytometry and ELISA to measure ICOS expression and cytokine production.
Potential Biases
Potential bias in patient selection and treatment history, as some patients were on corticosteroids.
Limitations
The study's findings may not be generalizable due to the specific patient population and the focus on peripheral blood T cells.
Participant Demographics
22 patients with active SLE (21 females, 1 male), 17 patients with inactive SLE (16 females, 1 male), and 24 normal controls (22 females, 2 males).
Statistical Information
P-Value
0.0033
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website